Nektar Therapeutics
NASDAQ:NKTR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nektar Therapeutics
NASDAQ:NKTR
|
US |
|
E
|
Eiffage SA
SWB:EF3
|
FR |
|
S
|
Syensqo SA
XBRU:SYENS
|
BE |
|
Spacenet Enterprises India Ltd
NSE:SPCENET
|
IN |
|
V
|
Vow Green Metals AS
OSE:VGM
|
NO |
Nektar Therapeutics
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Pipeline momentum: REZPEG (rezpegaldesleukin) validated in Phase IIb for atopic dermatitis (AD) and alopecia areata (AA); Phase III in AD to start randomizing first patient in June 2026.
Durability: 36–52 week data in AD show maintenance and deepening of response (including up to fivefold increase in EASI‑100) with monthly or quarterly maintenance dosing.
Regulatory path: FDA alignment on Phase III AD design: 24‑week induction with 24 μg/kg twice monthly, rerandomization to monthly vs quarterly maintenance; first Phase III readout expected mid‑2028 and BLA target in 2029.
Commercial/label potential: Company plans to include ACQ‑5 (asthma control) in AD Phase III and seeks to include it in label; ~25% bioexperienced / 75% biologic‑naive enrollment planned.
Balance sheet: Year‑end 2025 cash and investments $245.8M; since year‑end raised ~ $476M net through a public offering and ATM activity; expects to end 2026 with ~$400–460M.
2026 spend guidance: Wide preliminary guidance as Phase III planning continues: R&D $200–250M, G&A $60–65M, and noncash royalty revenue $40–45M.
AA & T1D updates: 52‑week AA extension data to be reported in April 2026 (23 patients entered the 16‑week blinded extension); TrialNet‑sponsored Phase II in new‑onset type 1 diabetes expected to report initial data in 2027.
Safety database: REZPEG safety established in >1,000 patients, ~381 patient‑years of exposure; company highlights differentiated safety vs JAK inhibitors.
